Pivot-09: A Phase Iii Randomized Open-Label Study Of Bempegaldesleukin (Nktr-214) Plus Nivolumab Versus Sunitinib Or Cabozantinib (Investigator'S Choice) In Patients With Previously Untreated Advanced Renal Cell Carcinoma (Rcc)

Nizar M. Tannir,Neeraj Agarwal,Sumanta K. Pal,Daniel C. Cho,Maria Formiga,Jun Guo,Daniel J. George,Mary Ann Tagliaferri,Stina Mui Singel, Bridget A. O'Keeffe,Alison L. Hannah, Minna Balbas,Konstantin Penkov

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 18|浏览62

暂无评分

摘要

TPS763Background: Bempegaldesleukin (BEMPEG; NKTR-214) is a first-in-class interleukin-2 (IL-2) receptor pathway agonist that activates and expands effector T cells and natural killer cells in the ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要